EntheogeniX Biosciences Gets Going

Psilocybin, ibogaine, and many other psychedelic substances have yielded remarkable early signals of their efficacy in treating everything from depression to various forms of addiction. And while Dr. Srinivas Rao, Chief Executive Officer of EntheogeniX Biosciences, shares the cautious optimism of many researchers, he’s careful to point out that these and other substances come with two significant obstacles: